Weight Loss Injections May Alter Taste and Smell, Studies Suggest

Patients undergoing treatment with GLP-1 medications, such as Ozempic, are reporting significant changes in their sense of taste and smell, with some experiencing a diminished enjoyment of food and aversions to previously favored fragrances. Professor Gal Dubnov-Raz, director of the obesity clinic at Safra Children's Hospital, noted that these changes have been observed over the past two years, with some women reporting altered perceptions of perfume scents after starting GLP-1 treatments.

The potential link between GLP-1 drugs and altered scent preferences has captured the attention of the perfume industry, with major companies like L'Oreal investigating the phenomenon. Reports indicate that some users develop an aversion to their former favorite perfumes, while others find new scents more appealing. Simultaneously, there has been an observed increase in interest in perfumery, with experts hypothesizing that individuals may seek alternative sources of pleasure, such as fragrances, as food becomes less enjoyable.

Research is beginning to shed light on these reported changes. A study published in JAMA Otolaryngology-Head & Neck Surgery, involving over 438,000 patients with type 2 diabetes, found that those taking GLP-1 medications had a 48% higher risk of taste and smell disturbances over two years compared to a control group. The risk of olfactory impairment was 81% higher, and taste impairment was 52% higher, though these instances remained rare, affecting fewer than 4 in 1,000 patients.

Another study from the University of Pennsylvania examined 46 patients on these medications and found a significant decrease in sensitivity to sweet, salty, sour, bitter, and umami tastes in 85% of participants, without detecting changes in smell. However, less than a quarter of these patients self-reported taste deterioration. The exact mechanisms behind these sensory changes are still under investigation, with theories suggesting a direct impact on brain pathways involved in smell and taste processing.

While a study by NIQ indicated that patients on GLP-1 treatments spend 26% more on perfumes, this spending increase was also observed for other cosmetics, making a direct link to altered scent preferences inconclusive. Professor Dubnov-Raz cautioned against developing specialized perfumes for this patient group, stating that while research and social media feedback are revealing additional effects of weight loss drugs, there is currently insufficient data to support such a development.